Custom Index Systems LLC Buys 3,897 Shares of Hologic, Inc. (NASDAQ:HOLX)

Custom Index Systems LLC raised its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 80.1% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 8,761 shares of the medical equipment provider’s stock after buying an additional 3,897 shares during the quarter. Custom Index Systems LLC’s holdings in Hologic were worth $714,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the company. Price T Rowe Associates Inc. MD raised its stake in Hologic by 77.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 6,297,197 shares of the medical equipment provider’s stock valued at $490,931,000 after buying an additional 2,753,016 shares during the last quarter. Swedbank AB purchased a new position in shares of Hologic in the 1st quarter valued at approximately $120,827,000. Black Creek Investment Management Inc. boosted its stake in Hologic by 60.9% in the 2nd quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider’s stock worth $173,669,000 after purchasing an additional 885,524 shares in the last quarter. Mackenzie Financial Corp grew its position in Hologic by 1,023.3% during the 2nd quarter. Mackenzie Financial Corp now owns 895,699 shares of the medical equipment provider’s stock worth $66,506,000 after purchasing an additional 815,960 shares during the last quarter. Finally, Marshall Wace LLP acquired a new position in Hologic during the 2nd quarter valued at approximately $39,427,000. 94.73% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Hologic news, insider Brandon Schnittker sold 476 shares of the business’s stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $83.11, for a total transaction of $39,560.36. Following the completion of the sale, the insider now directly owns 3,735 shares in the company, valued at approximately $310,415.85. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, insider Benjamin Jordan Cohn sold 5,093 shares of the company’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $81.99, for a total transaction of $417,575.07. Following the completion of the sale, the insider now owns 10,476 shares of the company’s stock, valued at approximately $858,927.24. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Brandon Schnittker sold 476 shares of the firm’s stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $83.11, for a total transaction of $39,560.36. Following the completion of the transaction, the insider now directly owns 3,735 shares in the company, valued at $310,415.85. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.75% of the company’s stock.

Hologic Price Performance

NASDAQ HOLX traded down $0.08 during trading hours on Friday, reaching $80.83. The company’s stock had a trading volume of 1,318,290 shares, compared to its average volume of 1,407,811. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.99 and a quick ratio of 3.32. Hologic, Inc. has a 1-year low of $64.02 and a 1-year high of $84.67. The company’s 50-day moving average is $80.92 and its two-hundred day moving average is $77.86. The firm has a market capitalization of $18.77 billion, a price-to-earnings ratio of 27.49, a P/E/G ratio of 2.96 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last announced its earnings results on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.04. The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The business’s revenue was up 2.7% on a year-over-year basis. During the same quarter last year, the firm posted $0.93 EPS. On average, equities analysts predict that Hologic, Inc. will post 4.09 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on HOLX. Needham & Company LLC reissued a “buy” rating and set a $90.00 price objective on shares of Hologic in a report on Tuesday, October 15th. StockNews.com lowered Hologic from a “strong-buy” rating to a “buy” rating in a report on Friday, September 27th. Leerink Partners decreased their target price on Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Stephens reiterated an “overweight” rating and issued a $92.00 price target on shares of Hologic in a report on Tuesday, July 30th. Finally, Royal Bank of Canada reissued a “sector perform” rating and set a $82.00 price target on shares of Hologic in a research report on Friday, August 16th. Five investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $87.50.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.